Humacyte Receives First of FDA’s Regenerative Medicine Designations
By Zachary Brennan -
Published 20 March 2017
The US Food and Drug Administration (FDA) on Monday offered one of its first Regenerative Medicine Advanced Therapy (RMAT) designations to Humacyte’s investigational human acellular vessel (HAV) Humacyl.
Categories: News, US, CBER, Biologics and biotechnology, Government affairs, Regulatory intelligence, Regulatory strategy
Tags: RMAT designation, regenerative medicine, 21st Century Cures